|
US4476116A
(en)
|
1982-12-10 |
1984-10-09 |
Syntex (U.S.A.) Inc. |
Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
EP0215942B1
(en)
|
1985-03-15 |
1995-07-12 |
Antivirals Inc. |
Polynucleotide assay reagent and method
|
|
US4866042A
(en)
|
1987-11-18 |
1989-09-12 |
Neuwelt Edward A |
Method for the delivery of genetic material across the blood brain barrier
|
|
US6294520B1
(en)
|
1989-03-27 |
2001-09-25 |
Albert T. Naito |
Material for passage through the blood-brain barrier
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US7101993B1
(en)
|
1990-01-11 |
2006-09-05 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides containing 2′-O-modified purines
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
BR9106826A
(pt)
|
1990-08-13 |
1994-01-25 |
Isis Pharmaceuticals Inc |
Oligonucleotideo ou analogo de oligonucleotideo,processo para modular a producao de uma proteina por um organismo,para tratar um organismo e processos para sintetizar:9(2'-desoxi-2'-substituido-beta-d-ribofuranosil)-guanina e g('-desoxi-2'-fluor-beta-d-ribofuranosil)-guanina
|
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
|
EP0651759B1
(en)
|
1992-07-23 |
2003-12-10 |
Isis Pharmaceuticals, Inc. |
Novel 2'-o-alkyl nucleosides and phosphoramidites processes for the preparation and uses thereof
|
|
AU692423B2
(en)
|
1992-09-25 |
1998-06-11 |
Institut National De La Sante Et De La Recherche Medicale |
Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
|
|
ES2290951T3
(es)
|
1993-05-11 |
2008-02-16 |
The University Of North Carolina At Chapel Hill |
Oligonucleotidos antisentido que combaten el corte y empalme aberrante y metodos de uso de los mismos.
|
|
AU1322795A
(en)
|
1993-12-24 |
1995-07-17 |
Erasmus University Rotterdam |
Tuberous sclerosis 2 gene and uses thereof
|
|
US5656612A
(en)
|
1994-05-31 |
1997-08-12 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
|
FR2727867B1
(fr)
|
1994-12-13 |
1997-01-31 |
Rhone Poulenc Rorer Sa |
Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
|
|
US6166197A
(en)
|
1995-03-06 |
2000-12-26 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
|
|
PL328563A1
(en)
|
1996-02-14 |
1999-02-01 |
Isis Pharmaceuticals Inc |
Oligonucleotides of modified sugar residues
|
|
GB9605808D0
(en)
|
1996-03-20 |
1996-05-22 |
Isis Innovation |
CFTR gene regulator
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
DE69832798T2
(de)
|
1997-06-03 |
2006-09-14 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.
|
|
US6963589B1
(en)
|
1997-07-03 |
2005-11-08 |
Canon Kabushiki Kaisha |
Information processing apparatus for and method of transmitting and/or receiving broadcast signal
|
|
US6391452B1
(en)
|
1997-07-18 |
2002-05-21 |
Bayer Corporation |
Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
|
|
GB9716231D0
(en)
|
1997-07-31 |
1997-10-08 |
Amersham Int Ltd |
Base analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
ATE293123T1
(de)
|
1997-09-12 |
2005-04-15 |
Exiqon As |
Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7045610B2
(en)
|
1998-04-03 |
2006-05-16 |
Epoch Biosciences, Inc. |
Modified oligonucleotides for mismatch discrimination
|
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
|
US7071324B2
(en)
|
1998-10-13 |
2006-07-04 |
Brown University Research Foundation |
Systems and methods for sequencing by hybridization
|
|
US20030224514A1
(en)
|
2002-05-31 |
2003-12-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of PPAR-delta expression
|
|
US6436657B1
(en)
|
1998-12-18 |
2002-08-20 |
E. I. Du Pont De Nemours And Company |
Polynucleotides encoding aminomethyltransferases
|
|
DK1152009T4
(en)
|
1999-02-12 |
2017-12-11 |
Daiichi Sankyo Co Ltd |
HIS UNKNOWN NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGS
|
|
JP2002540118A
(ja)
|
1999-03-18 |
2002-11-26 |
エクシコン エ／エス |
キシロ−ｌｎａ類似体
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
|
EP1163250B1
(en)
|
1999-03-24 |
2006-07-12 |
Exiqon A/S |
Improved synthesis of ¬2.2.1|bicyclo nucleosides
|
|
US6383752B1
(en)
|
1999-03-31 |
2002-05-07 |
Hybridon, Inc. |
Pseudo-cyclic oligonucleobases
|
|
ATE356824T1
(de)
|
1999-05-04 |
2007-04-15 |
Santaris Pharma As |
L-ribo-lna analoge
|
|
US6083482A
(en)
|
1999-05-11 |
2000-07-04 |
Icn Pharmaceuticals, Inc. |
Conformationally locked nucleosides and oligonucleotides
|
|
US6531591B1
(en)
|
1999-07-07 |
2003-03-11 |
Exiqon A/S |
Synthesis of stable quinone and photoreactive ketone phosphoramidite reagents for solid phase synthesis of photoreactive-oligomer conjugates
|
|
JP4151751B2
(ja)
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
|
US6677445B1
(en)
|
1999-08-27 |
2004-01-13 |
Chiron Corporation |
Chimeric antisense oligonucleotides and cell transfecting formulations thereof
|
|
US6187586B1
(en)
|
1999-12-29 |
2001-02-13 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of AKT-3 expression
|
|
KR20020097241A
(ko)
|
2000-05-04 |
2002-12-31 |
에이브이아이 바이오파마 인코포레이티드 |
스플라이스-영역 안티센스 조성물 및 방법
|
|
US6809194B1
(en)
|
2000-05-10 |
2004-10-26 |
Chiron Corporation |
Akt3 inhibitors
|
|
WO2002006529A2
(en)
|
2000-07-13 |
2002-01-24 |
The Johns Hopkins University School Of Medicine |
Detection and treatment of polycystic kidney disease
|
|
EP1314734A1
(en)
|
2000-08-29 |
2003-05-28 |
Takeshi Imanishi |
Novel nucleoside analogs and oligonucleotide derivatives containing these analogs
|
|
DE50113568D1
(de)
|
2000-09-02 |
2008-03-20 |
Gruenenthal Gmbh |
Antisense oligonukleotide gegen vr 1
|
|
US6998484B2
(en)
|
2000-10-04 |
2006-02-14 |
Santaris Pharma A/S |
Synthesis of purine locked nucleic acid analogues
|
|
JP2002345489A
(ja)
|
2000-11-03 |
2002-12-03 |
Astrazeneca Ab |
化学物質
|
|
EP1409497B1
(en)
|
2001-07-12 |
2005-01-19 |
Santaris Pharma A/S |
Method for preparation of lna phosphoramidites
|
|
AU2002336367A1
(en)
|
2001-08-16 |
2003-03-03 |
The Regents Of The University Of Michigan |
Adamts13 genes and proteins and variants, and uses thereof
|
|
WO2003020739A2
(en)
|
2001-09-04 |
2003-03-13 |
Exiqon A/S |
Novel lna compositions and uses thereof
|
|
US6936589B2
(en)
|
2001-09-28 |
2005-08-30 |
Albert T. Naito |
Parenteral delivery systems
|
|
WO2003040395A2
(en)
|
2001-11-07 |
2003-05-15 |
Applera Corporation |
Universal nucleotides for nucleic acid analysis
|
|
WO2003068795A1
(en)
|
2002-02-13 |
2003-08-21 |
Takeshi Imanishi |
Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
CA2484526C
(en)
|
2002-05-08 |
2009-10-13 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
AU2003247610A1
(en)
|
2002-06-21 |
2004-01-06 |
Ptc Therapeutics, Inc. |
METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
|
|
US20040023220A1
(en)
|
2002-07-23 |
2004-02-05 |
Lawrence Greenfield |
Integrated method for PCR cleanup and oligonucleotide removal
|
|
CA2495085A1
(en)
|
2002-08-12 |
2004-02-19 |
The Regents Of The University Of Michigan |
Diagnosis and treatment of tuberous sclerosis
|
|
US20060058253A1
(en)
|
2002-08-12 |
2006-03-16 |
Benoit Chabot |
Methods to reprogram splice site selection in pre-messenger rnas
|
|
US7696345B2
(en)
|
2002-11-05 |
2010-04-13 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
|
WO2004044133A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
|
DE60329220D1
(de)
|
2002-11-18 |
2009-10-22 |
Santaris Pharma As |
Antisense-entwurf
|
|
US7790867B2
(en)
*
|
2002-12-05 |
2010-09-07 |
Rosetta Genomics Inc. |
Vaccinia virus-related nucleic acids and microRNA
|
|
WO2004080406A2
(en)
|
2003-03-07 |
2004-09-23 |
Alnylam Pharmaceuticals |
Therapeutic compositions
|
|
CA2524255C
(en)
|
2003-03-21 |
2014-02-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
ES2332178T5
(es)
|
2003-03-21 |
2014-02-04 |
Santaris Pharma A/S |
Análogos de ARN pequeños de interferencia (ARNpi)
|
|
CA2520550A1
(en)
|
2003-04-13 |
2004-10-28 |
Enzon Pharmaceuticals, Inc. |
Polymeric oligonucleotide prodrugs
|
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
|
US20070009899A1
(en)
*
|
2003-10-02 |
2007-01-11 |
Mounts William M |
Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
|
|
GB0326578D0
(en)
|
2003-11-14 |
2003-12-17 |
Univ Belfast |
Cancer diagnosis and therapy
|
|
US20050221354A1
(en)
|
2004-02-18 |
2005-10-06 |
Wyeth |
Nucleic acid arrays for monitoring expression profiles of drug target genes
|
|
EP1784501B1
(en)
|
2004-05-14 |
2015-11-18 |
Rosetta Genomics Ltd |
VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
US20070087376A1
(en)
|
2004-08-30 |
2007-04-19 |
Potashkin Judith A |
Splice variants of pre-mRNA transcripts as biomarkers in idiopathic neurodegenerative diseases
|
|
US20060134670A1
(en)
|
2004-11-19 |
2006-06-22 |
Fabrice Piu |
Enabling tools to identify ligands for hormone nuclear receptors
|
|
WO2006081311A2
(en)
|
2005-01-26 |
2006-08-03 |
Medical College Of Georgia Research Institute |
Compositions and methods for the intracellular disruption of vegf and vegfr-2 by intraceptors
|
|
WO2007094755A2
(en)
|
2005-02-04 |
2007-08-23 |
Massachusetts Institute Of Technology |
Compositions and methods for modulating cognitive function
|
|
ES2732071T3
(es)
|
2005-04-01 |
2019-11-20 |
Univ Florida |
Biomarcadores de lesiones hepáticas
|
|
WO2006119494A2
(en)
*
|
2005-05-04 |
2006-11-09 |
Exagen Diagnostics, Inc. |
Acute myelogenous leukemia biomarkers
|
|
US20070015703A1
(en)
|
2005-06-17 |
2007-01-18 |
Denisa Wagner |
ADAMTS13-containing compositions having thrombolytic activity
|
|
HUE027486T2
(en)
|
2005-06-23 |
2016-09-28 |
Isis Pharmaceuticals Inc |
Preparations and methods for modifying SMN2-Splicing
|
|
LT2578685T
(lt)
|
2005-08-23 |
2019-06-10 |
The Trustees Of The University Of Pennsylvania |
Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
|
|
WO2007028065A2
(en)
|
2005-08-30 |
2007-03-08 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds for modulation of splicing
|
|
US8258109B2
(en)
|
2005-10-20 |
2012-09-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of LMNA expression
|
|
WO2007048629A2
(en)
|
2005-10-28 |
2007-05-03 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modulation of rna silencing efficiency by argonaute proteins
|
|
EP1945765A2
(en)
|
2005-10-28 |
2008-07-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Structures of active guide rna molecules and method of selection
|
|
WO2007053747A2
(en)
|
2005-11-01 |
2007-05-10 |
President And Fellows Of Harvard College |
Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
|
|
US7785834B2
(en)
*
|
2005-11-10 |
2010-08-31 |
Ercole Biotech, Inc. |
Soluble TNF receptors and their use in treatment of disease
|
|
EP1792981A1
(en)
|
2005-12-02 |
2007-06-06 |
Humboldt-Universität zu Berlin |
Microginin producing proteins and nucleic acids encoding a microginin gene cluster as well as methods for creating microginins
|
|
ES2453380T3
(es)
|
2006-01-26 |
2014-04-07 |
Isis Pharmaceuticals, Inc. |
Composiciones y utilizaciones dirigidas hacia la huntingtina
|
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
|
AU2007211080B9
(en)
|
2006-01-27 |
2012-05-03 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
|
CA2640058C
(en)
|
2006-01-27 |
2018-04-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
|
US8007790B2
(en)
|
2006-04-03 |
2011-08-30 |
Stowers Institute For Medical Research |
Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
|
|
US8586554B2
(en)
|
2006-05-05 |
2013-11-19 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of PTP1B
|
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
|
WO2007134181A2
(en)
|
2006-05-11 |
2007-11-22 |
Isis Pharmaceuticals, Inc. |
5'-modified bicyclic nucleic acid analogs
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
KR20090018859A
(ko)
|
2006-06-08 |
2009-02-23 |
가부시키가이샤 아미노 압 가가쿠 |
ｉＮＯＳ의 발현 제어 작용을 갖는 센스 올리고뉴클레오티드 및 그것을 포함하는 조성물
|
|
WO2008001778A1
(fr)
|
2006-06-27 |
2008-01-03 |
Takeda Pharmaceutical Company Limited |
Animal génétiquement modifié et son utilisation
|
|
CA3081362C
(en)
|
2006-07-24 |
2024-04-09 |
Athena Diagnostics, Inc. |
Method of detecting the occurrence of adpkd based on presence of nucleotide sequence alteration in pkd1
|
|
CA2667055C
(en)
|
2006-10-18 |
2017-05-09 |
Isis Pharmaceuticals, Inc. |
Antisense compounds
|
|
US20090264353A1
(en)
|
2007-10-19 |
2009-10-22 |
Santaris Pharma A/S |
Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
|
|
ATE551061T1
(de)
|
2006-11-13 |
2012-04-15 |
Santaris Pharma As |
Lna-nukleosid-phosphoramidate
|
|
US8293684B2
(en)
|
2006-11-29 |
2012-10-23 |
Exiqon |
Locked nucleic acid reagents for labelling nucleic acids
|
|
US8048998B2
(en)
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
|
EP2641971A1
(en)
|
2007-01-29 |
2013-09-25 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
|
KR101551985B1
(ko)
|
2007-03-09 |
2015-09-09 |
리가가쿠 겐큐쇼 |
모노뉴클레오시드 또는 모노뉴클레오티드로부터 유도되는 구조를 갖는 화합물, 핵산, 표지 물질, 핵산 검출 방법 및 키트
|
|
CL2008000696A1
(es)
|
2007-03-09 |
2008-09-12 |
Pioneer Hi Bred Int |
Polinucleotido aislado que codifica un modificador de un transportador de amonio (amt); casete de expresion y celula huesped que comprende la celula huesped; metodo para modular el amt en plantas.
|
|
EP2134736A4
(en)
|
2007-03-15 |
2013-05-29 |
Jyoti Chattopadhyaya |
FIVE- AND SIX-PIECE CONFORMATIVELY FIXED 2 ', 4'-CARBOCYCLIC RIBOTHYMIDINE FOR THE TREATMENT OF INFECTIONS AND CANCER
|
|
EP2149605B1
(en)
|
2007-03-22 |
2013-07-03 |
Santaris Pharma A/S |
Short RNA antagonist compounds for the modulation of target mRNA
|
|
CA2688321A1
(en)
|
2007-05-30 |
2008-12-11 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
|
US8278426B2
(en)
|
2007-06-08 |
2012-10-02 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
|
CN101796062B
(zh)
|
2007-07-05 |
2014-07-30 |
Isis制药公司 |
6-双取代双环核酸类似物
|
|
AU2008286771B2
(en)
|
2007-08-15 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
|
AU2008317566B2
(en)
|
2007-10-26 |
2014-05-01 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
EP2219680A2
(en)
|
2007-11-13 |
2010-08-25 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
|
US8546556B2
(en)
|
2007-11-21 |
2013-10-01 |
Isis Pharmaceuticals, Inc |
Carbocyclic alpha-L-bicyclic nucleic acid analogs
|
|
US20090247608A1
(en)
|
2007-12-04 |
2009-10-01 |
Alnylam Pharmaceuticals, Inc. |
Targeting Lipids
|
|
US8846386B2
(en)
|
2007-12-18 |
2014-09-30 |
University Of Kentucky Research Foundation |
sVEGFR-2 and its role in lymphangiogenesis modulation
|
|
WO2009084472A1
(ja)
|
2007-12-28 |
2009-07-09 |
Public University Corporation Yokohama City University |
新生児期～乳児期発症の難治性てんかんの検出方法
|
|
US20110065774A1
(en)
|
2008-01-31 |
2011-03-17 |
Alnylam Pharmaceuticals |
Chemically modified oligonucleotides and uses thereof
|
|
WO2009100320A2
(en)
|
2008-02-07 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
|
JP5409658B2
(ja)
|
2008-03-13 |
2014-02-05 |
セレラ コーポレーション |
静脈血栓症に関連した遺伝子多型、その検出方法および使用
|
|
EP2285819B1
(en)
|
2008-04-04 |
2013-10-16 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
|
|
WO2009124295A2
(en)
|
2008-04-04 |
2009-10-08 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
|
|
EP2119783A1
(en)
*
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
JP5559159B2
(ja)
|
2008-06-11 |
2014-07-23 |
バイオニュークレオン ソチエタ・レスポンサビリタ・リミタータ |
修飾オリゴヌクレオチドを使用するｈｒｐ−３の阻害
|
|
EP2151248A1
(en)
|
2008-07-30 |
2010-02-10 |
Johann Bauer |
Improved pre-mRNA trans-splicing molecule (RTM) molecules and their uses
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
WO2010036698A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
|
CA2735129C
(en)
|
2008-11-07 |
2012-06-26 |
Centre Hospitalier Universitaire Sainte-Justine |
Syngap1 dysfunctions and uses thereof in diagnostic and therapeutic applications for mental retardation
|
|
MX2011005912A
(es)
|
2008-12-04 |
2011-06-17 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
|
|
WO2010080509A1
(en)
|
2008-12-19 |
2010-07-15 |
Philadelphia Health And Education Corporation |
Compositions and methods for diminishing viral infection and inflammation associated with viral infection
|
|
US20100166784A1
(en)
|
2008-12-30 |
2010-07-01 |
The Washington University |
Method and compositions for modulating th17 cell development
|
|
DK2381965T3
(da)
|
2009-01-14 |
2020-07-27 |
Univ Drexel |
Modulation af præ-mrna under anvendelse af splejsningsmodulerende oligonukleotider som terapeutiske midler til behandling af sygdom
|
|
US9012139B2
(en)
|
2009-05-08 |
2015-04-21 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family
|
|
PL3449926T3
(pl)
|
2009-06-17 |
2020-06-01 |
Biogen Ma Inc. |
Kompozycje i sposoby modulacji składania smn2 u pacjenta
|
|
EP2275545A1
(en)
|
2009-07-16 |
2011-01-19 |
Julius-Maximilians-Universität Würzburg |
Use of microRNA-24 and/or its targets for the treatment and prevention of ischemia and induction of angiogenesis
|
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
|
US20120252877A1
(en)
|
2009-08-14 |
2012-10-04 |
Theramind Research, Llc |
Methods and compositions for treatment of tuberous sclerosis complex
|
|
WO2011031786A2
(en)
|
2009-09-08 |
2011-03-17 |
Laboratory Corporation Of America Holdings |
Compositions and methods for diagnosing autism spectrum disorders
|
|
WO2011032034A2
(en)
|
2009-09-10 |
2011-03-17 |
University Of Idaho |
Nucleobase-functionalized conformationally restricted nucleotides and oligonucleotides for targeting nucleic acids
|
|
CA2778171C
(en)
|
2009-10-29 |
2017-07-25 |
Osaka University |
Bridged artificial nucleoside and nucleotide
|
|
BR112012011195B1
(pt)
*
|
2009-11-12 |
2024-02-15 |
The University Of Western Australia |
Oligonucleotídeo antissentido, composição farmacêutica e uso de uma composição farmacêutica
|
|
WO2011066312A1
(en)
|
2009-11-25 |
2011-06-03 |
Elitech Holding B.V. |
Minor groove binder (mgb)-oligonucleotide mirna antagonists
|
|
WO2011085102A1
(en)
|
2010-01-11 |
2011-07-14 |
Isis Pharmaceuticals, Inc. |
Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
ES2733708T3
(es)
|
2010-02-08 |
2019-12-02 |
Ionis Pharmaceuticals Inc |
Reducción selectiva de variantes alélicas
|
|
US9193752B2
(en)
|
2010-03-17 |
2015-11-24 |
Isis Pharmaceuticals, Inc. |
5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
JP2013529181A
(ja)
|
2010-03-25 |
2013-07-18 |
ザ ジェイ． デヴィッド グラッドストーン インスティテューツ |
神経障害を治療するための組成物および方法
|
|
WO2011127210A1
(en)
|
2010-04-06 |
2011-10-13 |
Massachusetts Institute Of Technology |
Targeted delivery of nucleic acids
|
|
DK2560687T3
(en)
|
2010-04-19 |
2017-09-18 |
Nlife Therapeutics S L |
Preparations and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
|
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
|
US9156873B2
(en)
|
2010-04-28 |
2015-10-13 |
Isis Pharmaceuticals, Inc. |
Modified 5′ diphosphate nucleosides and oligomeric compounds prepared therefrom
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
CA2799944A1
(en)
|
2010-05-20 |
2011-11-24 |
University Of Rochester |
Methods and compositions related to modulating autophagy
|
|
WO2011156278A1
(en)
|
2010-06-07 |
2011-12-15 |
Isis Pharmaceuticals, Inc. |
Bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
US8846637B2
(en)
|
2010-06-08 |
2014-09-30 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
EP2582397A4
(en)
|
2010-06-15 |
2014-10-29 |
Isis Pharmaceuticals Inc |
COMPOUNDS AND METHOD FOR MODULATING INTERACTION BETWEEN PROTEINS AND TARGET NUCLEIC ACIDS
|
|
EP2585596B1
(en)
|
2010-06-23 |
2020-12-30 |
CuRNA, Inc. |
Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
|
|
RU2597972C2
(ru)
|
2010-10-22 |
2016-09-20 |
Курна Инк. |
Лечение заболеваний, связанных с геном альфа-l-идуронидазы (idua), путем ингибирования природного антисмыслового транскрипта гена idua
|
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
|
US20130309246A1
(en)
|
2011-02-02 |
2013-11-21 |
The Trustees Of Princeton University |
Jagged1 as a marker and therapeutic target for breast cancer bone metastasis
|
|
US20140128449A1
(en)
|
2011-04-07 |
2014-05-08 |
The Board Of Regents Of The University Of Texas System |
Oligonucleotide modulation of splicing
|
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
WO2013081755A1
(en)
|
2011-11-29 |
2013-06-06 |
Life Technologies Corporation |
Methods and compositions for multiplex pcr
|
|
EP3495497B1
(en)
|
2011-04-28 |
2021-03-24 |
Life Technologies Corporation |
Methods and compositions for multiplex pcr
|
|
US20140357558A1
(en)
|
2011-06-24 |
2014-12-04 |
Cold Spring Harbor Laboratory |
Compositions and methods for treatment of spinal muscular atrophy
|
|
BR112014001244A2
(pt)
|
2011-07-19 |
2017-02-21 |
Wave Life Sciences Pte Ltd |
métodos para a síntese de ácidos nucléicos funcionalizados
|
|
US8592156B2
(en)
|
2011-08-08 |
2013-11-26 |
Roche Molecular Systems, Inc. |
Predicting response to anti-CD20 therapy in DLBCL patients
|
|
US10023861B2
(en)
|
2011-08-29 |
2018-07-17 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
EA029151B1
(ru)
|
2011-09-06 |
2018-02-28 |
Курна, Инк. |
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АЛЬФА-СУБЪЕДИНИЦАМИ ПОТЕНЦИАЛЗАВИСИМЫХ НАТРИЕВЫХ КАНАЛОВ (SCNxA), С ПОМОЩЬЮ МАЛЫХ МОЛЕКУЛ
|
|
WO2013043878A2
(en)
|
2011-09-20 |
2013-03-28 |
The George Washington University |
Alternative splicing variants of genes associated with prostate cancer risk and survival
|
|
KR20140091587A
(ko)
|
2011-11-11 |
2014-07-21 |
산타리스 팔마 에이/에스 |
Smn2 스플라이싱의 조절을 위한 화합물
|
|
US9534222B2
(en)
|
2011-11-15 |
2017-01-03 |
University Of Utah Research Foundation |
Morpholinos, morpholino upregulating, and associated methods
|
|
WO2013106770A1
(en)
|
2012-01-11 |
2013-07-18 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of ikbkap splicing
|
|
WO2013120003A1
(en)
|
2012-02-08 |
2013-08-15 |
Isis Pharmaceuticals, Inc. |
Modulation of rna by repeat targeting
|
|
NZ628186A
(en)
|
2012-02-10 |
2016-03-31 |
Ptc Therapeutics Inc |
Compounds for treating spinal muscular atrophy
|
|
US8846885B2
(en)
|
2012-02-17 |
2014-09-30 |
Ajinomoto Co., Inc. |
Oligonucleotide with protected base
|
|
EP2850092B1
(en)
|
2012-04-09 |
2017-03-01 |
Ionis Pharmaceuticals, Inc. |
Tricyclic nucleic acid analogs
|
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
|
US20140378526A1
(en)
|
2012-05-11 |
2014-12-25 |
City Of Hope |
Design of nucleic acid binding molecules with non-watson crick and non-canonical pairing based on artificial mutation consensus sequences to counter escape mutations
|
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
|
US20150267192A1
(en)
|
2012-06-08 |
2015-09-24 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
|
SG10201912895PA
(en)
|
2012-07-13 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral control
|
|
US8729263B2
(en)
|
2012-08-13 |
2014-05-20 |
Novartis Ag |
1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
|
|
WO2014031575A1
(en)
|
2012-08-20 |
2014-02-27 |
The Regents Of The University Of California |
Polynucleotides having bioreversible groups
|
|
WO2014045283A1
(en)
|
2012-09-24 |
2014-03-27 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Restoration of the cftr function by splicing modulation
|
|
WO2014049536A2
(en)
|
2012-09-25 |
2014-04-03 |
Universidade De Lisboa |
Drug targets for cystic fibrosis and other conditions
|
|
EP2900682A1
(en)
|
2012-09-27 |
2015-08-05 |
IDENIX Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
|
UA116639C2
(uk)
|
2012-10-09 |
2018-04-25 |
Рег'Юлес Терап'Ютікс Інк. |
Способи лікування синдрому альпорта
|
|
US9029335B2
(en)
|
2012-10-16 |
2015-05-12 |
Isis Pharmaceuticals, Inc. |
Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
|
|
WO2014066915A2
(en)
|
2012-10-26 |
2014-05-01 |
Smith Larry J |
Methods and compositions to produce ss-rnai activity with enhanced potency
|
|
US9909128B2
(en)
|
2012-11-15 |
2018-03-06 |
The Regents Of The University Of California |
Splice modulating oligonucleotides that inhibit cancer
|
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
CN104004826B
(zh)
|
2013-01-07 |
2016-03-02 |
赵晨 |
突变的基因prpf4在制备遗传性视网膜疾病诊断试剂中的应用
|
|
EP2946019A1
(en)
|
2013-01-18 |
2015-11-25 |
Anna Mary Rose |
Therapeutics and diagnostics based on minisatellite repeat element 1 (msr1)
|
|
EP2951304B1
(en)
|
2013-02-04 |
2020-07-08 |
Ionis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
|
EP2957567B1
(en)
|
2013-02-18 |
2019-06-05 |
Shionogi & Co., Ltd. |
Nucleoside and nucleotide, having nitrogen-containing hetercycle structure
|
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
|
EP2981542B1
(en)
|
2013-04-01 |
2021-09-15 |
Idenix Pharmaceuticals LLC |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
WO2014172698A1
(en)
|
2013-04-19 |
2014-10-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
|
CN105378082B
(zh)
|
2013-05-01 |
2020-06-09 |
Ionis制药公司 |
组合物和方法
|
|
EP3008184A1
(en)
|
2013-06-13 |
2016-04-20 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of erythropoietic protoporphyria
|
|
WO2014201413A1
(en)
|
2013-06-14 |
2014-12-18 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating non-coding rna
|
|
CA2913785C
(en)
|
2013-06-25 |
2021-08-31 |
F. Hoffmann-La Roche Ag |
Compounds for treating spinal muscular atrophy
|
|
US20160201063A1
(en)
|
2013-08-16 |
2016-07-14 |
Rana Therapeutics, Inc. |
Epigenetic regulators of frataxin
|
|
MX2016002044A
(es)
|
2013-08-16 |
2016-08-17 |
Rana Therapeutics Inc |
Composiciones y metodos para modular el acido ribonucleico.
|
|
US20160201064A1
(en)
|
2013-08-16 |
2016-07-14 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin
|
|
JP2016531570A
(ja)
|
2013-08-16 |
2016-10-13 |
ラナ セラピューティクス インコーポレイテッド |
ユークロマチン領域を標的とするオリゴヌクレオチド
|
|
BR112015032718A2
(pt)
|
2013-08-19 |
2019-09-17 |
Hoffmann La Roche |
composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
|
|
EP3690048A1
(en)
|
2013-09-04 |
2020-08-05 |
Cold Spring Harbor Laboratory |
Reducing nonsense-mediated mrna decay
|
|
IL282239B2
(en)
|
2013-09-05 |
2023-10-01 |
Sarepta Therapeutics Inc |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
ES2739850T3
(es)
|
2013-09-11 |
2020-02-04 |
Synthena Ag |
Acidos nucleicos y procedimientos para el tratamiento de la enfermedad de Pompe
|
|
KR102524543B1
(ko)
|
2014-06-10 |
2023-04-20 |
에라스무스 유니버시티 메디컬 센터 로테르담 |
폼페병의 치료에 유용한 안티센스 올리고뉴클레오티드
|
|
GB201410693D0
(en)
*
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
|
GB201411468D0
(en)
|
2014-06-27 |
2014-08-13 |
Univ Edinburgh |
Novel treatment for endometriosis
|
|
WO2016027168A2
(en)
|
2014-08-20 |
2016-02-25 |
Lifesplice Pharma Llc |
Splice modulating oligonucleotides and methods of use thereof
|
|
US11198874B2
(en)
|
2014-08-20 |
2021-12-14 |
Lifesplice Pharma Llc |
SCN8A splice modulating oligonucleotides and methods of use thereof
|
|
JP6867945B2
(ja)
|
2014-10-03 |
2021-05-12 |
コールド スプリング ハーバー ラボラトリー |
核内遺伝子出力の標的とされた増強
|
|
WO2016061509A1
(en)
|
2014-10-17 |
2016-04-21 |
The Broad Institute, Inc. |
Compositions and methods of treatng muscular dystrophy
|
|
AU2015346042A1
(en)
|
2014-11-14 |
2017-04-27 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of proteins
|
|
GB201421379D0
(en)
|
2014-12-02 |
2015-01-14 |
Isis Innovation Ltd And Medical Res Council |
Molecule
|
|
CN114642735A
(zh)
|
2015-01-21 |
2022-06-21 |
菲泽尔克斯公司 |
用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
|
|
WO2016128343A1
(en)
|
2015-02-09 |
2016-08-18 |
F. Hoffmann-La Roche Ag |
Compounds for the treatment of cancer
|
|
US9840709B2
(en)
|
2015-02-20 |
2017-12-12 |
Rosalind Franklin University Of Medicine And Science |
Antisense compounds targeting genes associated with cystic fibrosis
|
|
MX2017011004A
(es)
|
2015-02-27 |
2018-02-09 |
Sarepta Therapeutics Inc |
Inclusion del exon2 inducida por antisentido en alfa-glucosidasa.acida.
|
|
HK1249140A1
(zh)
|
2015-04-03 |
2018-10-26 |
Ionis Pharmaceuticals, Inc. |
用於调节tmprss6表达的化合物和方法
|
|
EP3310169B1
(en)
|
2015-05-30 |
2023-05-17 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
|
US20180265911A1
(en)
|
2015-09-24 |
2018-09-20 |
The Trustees Of The University Of Pennsylvania |
Triptycene derivatives for nucleic acid junction stabilization
|
|
WO2017060731A1
(en)
|
2015-10-09 |
2017-04-13 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
GB2591194B
(en)
|
2015-10-09 |
2021-10-13 |
Univ Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
|
EP3390642B1
(en)
|
2015-12-14 |
2021-11-24 |
Cold Spring Harbor Laboratory |
Compositions for treatment of retinitis pigmentosa 13
|
|
AU2016370653A1
(en)
|
2015-12-14 |
2018-06-21 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of Autosomal Dominant Mental Retardation-5 and Dravet Syndrome
|
|
JP2018538288A
(ja)
|
2015-12-14 |
2018-12-27 |
コールド スプリング ハーバー ラボラトリー |
アラジール症候群の処置のためのアンチセンスオリゴマー
|
|
JP7049247B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
腎臓病の処置のための組成物と方法
|
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
|
JP7049249B2
(ja)
|
2015-12-14 |
2022-04-06 |
コールド スプリング ハーバー ラボラトリー |
中枢神経系疾患の処置のための組成物および方法
|
|
EP3389782A4
(en)
|
2015-12-14 |
2019-07-31 |
Cold Spring Harbor Laboratory |
ANTISENSE OLIGOMERS FOR THE TREATMENT OF A POLYCYSTIC KIDNEY DISEASE
|
|
WO2017106375A1
(en)
|
2015-12-14 |
2017-06-22 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of tuberous sclerosis complex
|
|
EP3390634A4
(en)
|
2015-12-14 |
2019-08-14 |
Cold Spring Harbor Laboratory |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES
|
|
EP3389672A4
(en)
|
2015-12-14 |
2019-08-14 |
Cold Spring Harbor Laboratory |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF LIVER DISEASES
|
|
MX2019011772A
(es)
|
2017-04-03 |
2020-01-09 |
Encoded Therapeutics Inc |
Expresion transgenica selectiva de tejidos.
|
|
LT3673080T
(lt)
|
2017-08-25 |
2023-12-27 |
Stoke Therapeutics, Inc. |
Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
|
|
US20210268667A1
(en)
|
2017-10-23 |
2021-09-02 |
Stoke Therapeutics, Inc. |
Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases
|